StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Monday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their target price on Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a research report on Monday, March 4th.

Aethlon Medical Trading Down 2.3 %

AEMD opened at $1.25 on Monday. The stock has a market cap of $3.28 million, a PE ratio of -0.25 and a beta of 1.95. The stock’s fifty day simple moving average is $1.58 and its 200 day simple moving average is $1.74. Aethlon Medical has a 1-year low of $1.25 and a 1-year high of $5.00.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). Equities analysts forecast that Aethlon Medical will post -4.98 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.